MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Skanray and Tata Elxsi Collaborate to Innovate Surgical Imaging and Healthcare Solutions

NextEdge Admin

06 Aug 2024

2 min 34 sec

Skanray, a global leader in MedTech R&D and manufacturing, specializing in diagnostic imaging, critical care, and surgical solutions, has partnered with Tata Elxsi to develop advanced surgical imaging core technology and software platforms. This collaboration aims to revolutionize diagnosis and treatment by leveraging cutting-edge technology for predictability, accuracy, and consistency.

Skanray is expanding its portfolio to include new device families and modalities, focusing on building reusable modules and components for medical devices and developing an advanced analytics cloud platform.

Tata Elxsi will spearhead a software platform-led approach to diagnostics, supporting all imaging, critical care, and surgical systems from Skanray, ensuring interoperability and multi-modal functionality. The platform will incorporate the latest AI and GenAI technologies and process efficiencies.

This collaboration combines Skanray's expertise in medical devices and core component technology with Tata Elxsi's domain experience in medical imaging, software platform development, digital capabilities in cloud, AI, and analytics. This synergy aims to redefine the medical technology landscape with advanced, modular, and affordable diagnostic systems.

Pankaj Madhukar Wani, Head of Healthcare Business Unit at Tata Elxsi, stated, "The diagnostic imaging landscape is being transformed by software and digital technologies such as cloud and AI. We are delighted to support Skanray in realizing their long-term strategy and vision for healthcare. This partnership will create transformative solutions for healthcare facilities and patients worldwide."

Priyanka Chatterjee, VP – Corporate Communications at Skanray Technologies Ltd., added, "Our collaboration will drive significant advancements in healthcare delivery, resulting in technologically advanced, operator-friendly, and cost-effective solutions, helping healthcare providers deliver significantly improved health outcomes for patients."